©2024 Stanford Medicine
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Recruiting
I'm InterestedTrial ID: NCT00373347
Purpose
The purpose of this study is to identify blood markers that have the ability to diagnose
liver cancer with improved accuracy, so that it can be used alone or in conjunction with
alpha-feto protein (AFP)
Official Title
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Stanford Investigator(s)
Samuel So, MD
Lui Hac Minh Professor in the School of Medicine
Eligibility
Inclusion Criteria:
- Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated
with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI.
- Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or
nodular hyperplasia.
- Patients with hepatitis B or hepatitis C viral infections not associated with liver
cancer.
Exclusion Criteria:
-Patients will be excluded if, upon looking through their medical records, information
required for data analysis are missing.
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mei-Sze Chua
650-724-3525